with '251-labelled wheat-germ agglutinin with that bound at mol.wt. 100000 with 12JI-labelled concanavalin A PGI9-G cells were incubated and treated as in Fig. I , except that 1251-labelled wheat-germ agglutinin was used in place of 1251-labelled concanavalin A.
concanavalin A-binding proteins are relatively unaffected by the changes in glucose concentration. At this threshold level of glucose the glucose-regulated proteins of Shui et al. (1977) are not apparent.
The reappearance of the 100000-mol.wt. glycoprotein can be correlated with the reappearance of the 95 000-mol.wt. glucosamine-labelled glycoprotein ( Fig. 2 ) and there seems, therefore, good reason to believe that they are linked in some way or involved together in glucose metabolism.
The induction of the 100000-mol.wt. glycoprotein is specific for Dglucose and D-mannose at concentrations above 300mg/ litre. L-glucose. deoxy-D-glucose. 5-thio-D-glucose ahd Dgalactose are not inducers, even though deoxy-D-glucose and 5-thio-D-glucose are supposed to enter the cell using the same carrier as D-glucose. Not surprisingly the induction is completely inhibited by cytochalasin B, but is unaffected by cytochalasins A. C or D (Kletzien el al., 1972) . It has also been shown that PGI9-G cells grown in low levels of glucose bind only 50% of labelled cytochalasin B compared with the same cells grown in normal levels of glucose, thus providing additional evidence that the glucose carrier protein is much reduced in these cells. Addition of emetine, a specific protein inhibitor, just before glucose is sufficient to completely block the inductive effect, showing that protein synthesis must take place if induction of the 100000-mol.wt. glycoprotein is to occur. Recently it has been demonstrated by radiation-target-size theory that the glucose carrier in human erythrocytes is most likely a protein of mol.wt. 200000 which exists as a dimer of mol.wt.-100000 or a tetramer of mol.wt.-50000 subunits (Jung et al., 1980) . Also using a more specific glucose-transport blocking reagent, maltosyl isothiocyanate, Mullins 8c Langdon (1980) confirmed that in the human erythrocyte the glucose carrier is contained in the band 3 proteins (mol.wt. 90000-lOO000).
It thus seems highly probable that the changes seen in the 100000-rno1.w. and 90000-mol.wt. glycoproteins in malignant transformation are directly related to the glucose uptake by these cells and may well be linked to the glucose-regulated proteins seen by other workers (Shiu et al., 1977; McCormick et al., 1979) , but distinct from them, since the former are present in only very small amounts. The mammalian platelet is a specialized anucleate cell is released in large numbers into the bloodstream from its parent cell, the megakaryocyte, in the bone marrow. Its primary functional role is in the arrest of bleeding and the maintenance of haemostasis. Platelets adhere to exposed subendothelial components of the vessel wall, and this is followed by the formation of platelet aggregates or thrombi at the injured site.
We have studied the membrane structure of platelets isolated from patients with hereditary bleeding disorders characterized by defects of different aspects of platelet function. Such disorders are specifically termed 'constitutional thrombocytopathia'. An example is Glanzmann's thrombasthenia (see Hardisty, 1977) . Platelets from these patients adhere normally to subendothelium (Baumgartner et al., 1977) : however, no subsequent thrombus formation occurs. A characteristic common to the platelets of all thrombasthenic patients is their inability to aggregate after stimulation by all physiological aggregation-inducing agents. As discussed elsewhere (Nurden & Caen, 1979) . thrombasthenic-patients' platelets appear unable to form the linking bonds necessary for the final formation of the aggregates. Nurden & Caen (1974) studied membrane fractions isolated from thrombasthenic-patients' platelets and noted the presence of glycoprotein abnormalities. SDS*/polyacrylamide-gel electrophoresis followed by periodate-Schiff staining revealed marked decreases in the staining intensity normally observed in the then-termed glycoprotein -11 and -111 regions of the gel. Molecular differences in the surface composition of thrombasthenic-patients' platelets were confirmed by Phillips et al.
(1 975) using the lactoperoxidase-catalysed procedure for * Abbreviation: SDS. sodium dodecyl sulphate. The surface proteins of platelets isolated from a normal individual, a patient (A. C.) with Glanzmann's thrombasthenia and a patient (W. B.) with the Bernard-Soulier syndrome were labelled with 1151 by the lactoperoxidase-catalysed procedure of Phillips & Poh Agin (1977a). The platelets were then solubilized by heating at 100°C for 5min with 2% (w/v) SDS in the presence of 5 mM-N-ethylmaleimide and 3 mM-EDTA. Samples (100,ug of protein) were analysed by SDS/po!yacrylamide-gel electrophoresis on 7-12% exponential-gradient acrylamide slab gels by the Laemmli (1970) procedure. Protein-stained gels were dried and subjected to radioautography using Kodak X-OMat MA film. Densitometric scans of typical '251-labelling profiles are illustrated.
labelling cell-surface proteins with 1151 or 1311. Fig. 1 illustrates the abnormal surface structure of thrombasthenic-patients' platelets. Phillips & Poh Agin ( 1 9 7 7~) should be consulted as a guide to the complex nature of the platelet membrane glycoprotein composition as revealed by current electrophoresis procedures. Many of the glycoproteins are large ( M , > 100000) and possess characteristic contents of inter-or intra-molecular disulphide bonds. Early studies were unable to distinguish betwetn molecular deficiencies in thrombasthenic-patients platelets and the possible presence of structurally modified glycoproteins. Platelets from a large number of thrombasthenic patients have now been examined by a number of different radiolabelling and SDS/ polyacrylamide-gel-electrophoresis procedures (Phillips & Poh Agin, 19776 & Caen, 1979) . Accumulated evidence from these studies suggests severe molecular deficiencies of glycoproteins IIb and IIIa as a specific membrane defect of thrombasthenic-patients' platelets. This conclusion has recently been supported by immunological data. first showed that the platelet-specific alloantigen Vol. 8 PIA1 was deleted from platelets in thrombasthenia and then proved (Kunicki & Aster, 1979 ) that the PIA1 antigenic marker was associated with glycoprotein IIIa on normal human platelets. Hagen et a/.
(1 980) studied Triton-X-100-solubilized normal and thrombasthenic-patients' platelets by crossed immunoelectrophoresis using a polyspecific rabbit antiserum against normal human platelets. A prominent 1251-labelled immunoprecipitate, termed band 16, was significantly diminished in intensity in the patterns obtained for 1251-labelled platelets from thrombasthenic patients. Platelets from nine thrombasthenic patients have now been analysed by crossed immunoelectrophoresis in our laboratory; the results obtained for three patients as reported by Hagen et al. (1980) and those studied subsequently all showed either the absence of band 16 (six patients) or its presence in severely diminished quantities (< 15%). All other major 1Z51-labelled precipitates were in their normal positions on the agarose plate. Band 16 was excised from the agarose gel after its precipitation from normal platelet samples by the rabbit anti-(human platelet) antibody preparation (Hagen et al., 1980) and analysed by SDS/polyacrylamide-gel electrophoresis. Glycoproteins IIb and IIIa were identified as the platelet antigens contained within the precipitate.
Like Glanzmann's thrombasthenia, the Bernard-Soulier syndrome is a platelet disorder with an autosomal recessive inheritance. When anticoagulated whole blood from patients and control subjects is circulated over arterial subendothelium under simulated blood-flow conditions. a defective adherence of the platelets of Bernard-Soulier-syndrome patients to the subendothelium is observed (Weiss et (1977) to speculate that the defect occurred during the initial platelet attachment to the vessel wall. Platelet aggregation as induced by ADP is normal in the Bernard-Soulier syndrome, thus clearly distinguishing the platelet-function defect from that observed in thrombasthenia. Furthermore, a diminished binding of 1251-labelled thrombin to Bernard-Soulier-syndrome platelets has been noted and correlated with a decreased aggregation response specifically observed with thrombin (Jamieson & Okumura, 1978) , Hardisty (1977) should be consulted for further details of platelet-function studies in the Bernard-Soulier syndrome.
A glycoprotein abnormality in Bernard-Soulier-syndrome platelets was first described by Nurden & Caen (1975) , who observed a much decreased carbohydrate staining of the then-termed glycoprotein I after the analysis of isolated platelet membranes by SDS/polyacrylamide-gel electrophoresis. A greater resolution of the platelet surface components has been achieved in subsequent studies, and the affected glycoprotein is now specifically termed glycoprotein Ib (see Nurden & Caen, 1979) . Membrane glycoprotein Ib is normally the predominant periodate-Schiff-staining glycoprotein observed after &he analysis of whole platelet suspensions by SDS/polyacrylamide-gel electrophoresis. It is the membrane precursor of glycocalicin (Solum et al., 1980) , a high-molecular-weight acidic glycopeptide located in the soluble phase after platelet homogenization in the presence of Ca2+. Glycocalicin has been isolated and characterized (Okumura et a/., 1976) , having an apparent mol.wt. of 148000 and consisting of 60% (by wt.) carbohydrate. It is rich in sialic acid, and is the most heavily labelled surface component when washed normal platelet suspensions are treated sequentially with neuraminidase, galactose oxidase and NaB3H, (Phillips & Poh Agin, 1977b) .
Bernard-Soulier-syndrome patients are extremely rare, and the defect is accompanied by a low circulating platelet count. A specific defect in the glycoprotein I region of periodateSchiff-stained gels after SDS/polyacrylamide gel electrophoresis has been confirmed in several studies (Caen et Fig. 1 illustrates the analysis of Bernard-Soulier-syndrome platelets whose surface proteins were labelled with lz5I by the lactoperoxidase-catalysed procedure. A specific absence of radioactivity in the glycoprotein-Ib region of the gel may be observed; the other major membrane glycoproteins are normally labelled. Confirmation of the presence of glycoprotein IIIa was provided by , who showed that BernardSoulier-syndrome platelets reacted normally with anti-(alloantigen P P ) antibody. observed, however, that Bernard-Soulier-syndrome platelets lacked another plateletspecific antigen marker, the receptor for quinine-and quinidinedependent antibodies. Recently we have shown that this receptor activity was associated with a glycoprotein-Ib-enriched fraction purified by chromatography of Triton-X-100-solubilized normal platelet membranes on wheat-germ-lectin affinity columns (A. T. Nurden, D. Dupuis, D. Pidard & T. J. Kunicki, unpublished work) . That the Bernard-Soulier-syndrome platelets actually lacked glycoprotein Ib was further suggested by the studies of Hagen et al. (1980) , who showed that a specific immunoprecipitate (band 13) was missing when Bernard-Souliersyndrome platelets were studied by crossed immunoelectrophoresis. Whereas band 13 was precipitated when normal human platelets were analysed against an antiserum prepared against isolated glycocalicin, no precipitate was observed with Bernard-Soulier-syndrome platelets.
In conclusion, we have described evidence to show that two hereditary platelet disorders characterized by defects involving the two major pathways of platelet function in haemostasis, i.e. adhesion and aggregation, are associated with qualitatively different membrane glycoprotein deficiencies. These appear to be platelet-specific abnormalities; analysis of membranes isolated from erythrocytes of patients of both disorders revealed no glycoprotein defects. Elucidation of the mechanisms of platelet adhesion and aggregation is particularly important in view of the possible platelet involvement in the pathological processes leading to atherosclerosis and thrombosis. Studies such as we have described may offer clues to those membrane components which mediate the surface contact interactions vital to the specific functional activities of this remarkable cell.
Viruses probably account for some 60% of infectious diseases in man (Thigpen, 1971) . In order to elicit a pathological change, viruses have to enter susceptible cells and to multiply within them: usually this is followed by release and infection of cells at other sites in the body. Since entry and release obviously involve the cell surface, viral infections constitute an important class of membrane disease.
To date, investigations of the cell surface have focused on two aspects: the characterization of binding sites that promote viral entry into cells, and the demonstration that, after multiplication of viral constituents within cells, viral antigens appear at the cell surface (e.g. Poste & Nicolson, 1977) . The latter effect underlies not only the action of the immune system in destroying virally infected cells, but may also play a role in the progression towards establishing an auto-immunity towards a particular component of the surface membrane; the outcome of that may be destruction of any cell bearing the component, long after virus has been eliminated from the body. The more immediate basis of viral disease has generally been ascribed to an inflammatory response resulting from the presence of damaged cells, a response that may be augmented by immune recognition of virally damaged cells. The purpose of the present article is to suggest that the surface membrane is involved in viral disease in a third way, and that this contributes not only to the cytopathic effect of viruses, but may underlie the physiological consequences of certain viral infections also. The property of the surface membrane to be discussed is that of controlling cellular permeability.
That the surface membrane becomes damaged in virally infected cells has been recognized for a long time. Infected cells leak protein (Gilbert, 1963; Blackman & Bubel, 1969; Cassels, 1973; Katzman & Wilson, 1974; Norkin, 1977; Schumperli et al., 1978) and becomes permeable to Trypan Blue; membrane rupture underlies the final stage of cellular disintegration. Such changes are clearly a consequence of intracellular events. More subtle permeability changes, on the other hand, may be the very cause of cytopathic damage. Thus it has been suggested that virally infected cells become permeable to Na+, and that a net entry of Na+ occurs: this is said to shift the balance between host-protein synthesis and viral-protein synthesis in favour of the latter process, and thus to amplify viral multiplication (Carrasco & Smith, 1976; Carrasco, 1978) . Moreover, if virally infected cells were to become permeable to ions and lowmolecular-weight compounds in general, such that essential constituents such as nucleotides (including cyclic ones) and other phosphorylated intermediates leak out, and potentially toxic ions such as Ca2+ (Kaiser & Edelman, 1977; Robbins & Cotran, 1979 ; Schanne et al., 1979) leak in, this would contribute significantly to the loss of cellular viability. Experiments carried out in our laboratory have shown that such changes do indeed occur.
Initially, we studied paramyxoviruses ( e g Sendai virus) that are known (Poste, 1972) to enter cells by fusion between viral envelope and surface membrane. During viral entry, phosphorylated compounds such as phosphocholine (Pasternak & Micklem, 1973) , sugar phosphates (Poste & Pasternak, 1978) 
